Incyte | INCY - Bruttoergebnis Vom Umsatz

Aktienkurs
90.30
Täglich Wechseln
-1.96 -2.12%
Monatlich
-9.74%
Jährlich
49.01%
Q1 Prognose
87.59




Bruttoergebnis Vom Umsatz Veränderung Datum
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agenus USD 34.2M 4.61M 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Nektar Therapeutics USD 13.75M 650K 2024-06
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Novartis USD 10.82B 694M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12